13F
中

PBYI PUMA BIOTECHNOLOGY INC

2026Q1 · CUSIP 74587V107 · Sector: Healthcare & Biotech

Neutral · No signal
Holders
156
Δ holders QoQ
+5
Breadth percentile
Top 43%
Whale holders
79
Δ whales
+2
Inst. holding value
$241M
New positions
29
Closed positions
24
Price momentum (1Q)
+0.9%
Put / Call
0/2

Breadth history (34 quarters)

2018Q1: Δ-22 · h=177 2018Q2: Δ-4 · h=173 2018Q3: Δ-16 · h=157 2018Q4: Δ-14 · h=143 2019Q1: Δ+14 · h=157 2019Q2: Δ-18 · h=139 2019Q3: Δ+5 · h=144 2019Q4: Δ-9 · h=135 2020Q1: Δ-8 · h=127 2020Q2: Δ+3 · h=130 2020Q3: Δ+0 · h=130 2020Q4: Δ-5 · h=125 2021Q1: Δ-5 · h=120 2021Q2: Δ+3 · h=123 2021Q3: Δ-5 · h=118 2021Q4: Δ-13 · h=105 2022Q1: Δ+0 · h=105 2022Q2: Δ-15 · h=90 2022Q3: Δ-7 · h=83 2022Q4: Δ+7 · h=90 2023Q1: Δ-10 · h=80 2023Q2: Δ-11 · h=69 2023Q3: Δ+1 · h=70 2023Q4: Δ+13 · h=83 2024Q1: Δ+11 · h=94 2024Q2: Δ+6 · h=100 2024Q3: Δ+1 · h=101 2024Q4: Δ+12 · h=113 2025Q1: Δ+4 · h=117 2025Q2: Δ+6 · h=123 2025Q3: Δ+10 · h=133 2025Q4: Δ+18 · h=151 2026Q1: Δ+5 · h=156 2018Q1: holders=177 2018Q2: holders=173 2018Q3: holders=157 2018Q4: holders=143 2019Q1: holders=157 2019Q2: holders=139 2019Q3: holders=144 2019Q4: holders=135 2020Q1: holders=127 2020Q2: holders=130 2020Q3: holders=130 2020Q4: holders=125 2021Q1: holders=120 2021Q2: holders=123 2021Q3: holders=118 2021Q4: holders=105 2022Q1: holders=105 2022Q2: holders=90 2022Q3: holders=83 2022Q4: holders=90 2023Q1: holders=80 2023Q2: holders=69 2023Q3: holders=70 2023Q4: holders=83 2024Q1: holders=94 2024Q2: holders=100 2024Q3: holders=101 2024Q4: holders=113 2025Q1: holders=117 2025Q2: holders=123 2025Q3: holders=133 2025Q4: holders=151 2026Q1: holders=156 -22 -11 +0 +11 +22 62124186 18Q119Q120Q121Q122Q123Q124Q125Q126Q1 Δ holders (bar) Holders (line)

Past Lit Events & Aftermath 0 lit events

No lit events in history

Options Sentiment

Put holders
0
QoQ: 0
Call holders
2
QoQ: -1

See methodology →

Fundamentals

PE (TTM)
17.3
EPS (TTM)
$0.48
EPS YoY
-38.5%
Revenue (TTM)
$0.2B
Revenue YoY
-2.4%
Quarterly Revenue & EPS (4Y)
2022-06-30: $60M 2022-09-30: $57M 2022-12-31: $66M 2023-03-31: $53M 2023-06-30: $55M 2023-09-30: $56M 2023-12-31: $72M 2024-03-31: $44M 2024-06-30: $47M 2024-09-30: $81M 2024-12-31: $59M 2025-03-31: $46M 2025-06-30: $52M 2025-09-30: $54M 2025-12-31: $75M 2026-03-31: $45M 2022-06-30: EPS 0.21 2022-09-30: EPS -0.01 2022-12-31: EPS -0.12 2023-03-31: EPS 0.03 2023-06-30: EPS 0.05 2023-09-30: EPS 0.12 2023-12-31: EPS 0.25 2024-03-31: EPS -0.10 2024-06-30: EPS -0.09 2024-09-30: EPS 0.41 2024-12-31: EPS 0.40 2025-03-31: EPS 0.06 2025-06-30: EPS 0.12 2025-09-30: EPS 0.17 2025-12-31: EPS 0.26 2026-03-31: EPS -0.07 0M 40M 81M $M -0.13 0.16 0.45 20222023202420252026 Revenue EPS

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time
4Y median 13 2023-03-31: PE 25.82023-09-30: PE 49.92023-12-31: PE 15.82024-03-31: PE 12.82024-06-30: PE 152024-09-30: PE 5.12024-12-31: PE 4.62025-03-31: PE 4.32025-06-30: PE 5.82025-09-30: PE 6.52025-12-31: PE 11.22026-03-31: PE 14.4 4 28 52 20222023202420252026

P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden

As of 2026-03-31 · SEC filings (XBRL)